{"title": "Sanofi, GSK post 58% efficacy in omicron-affected COVID-19 vaccine trial, teeing up race to regulators", "author": "Nick Paul Taylor", "url": "https://www.fiercebiotech.com/biotech/sanofi-gsk-post-58-efficacy-omicron-affected-covid-19-vaccine-trial-teeing-race-regulators", "hostname": "fiercebiotech.com", "description": "Sanofi and GlaxoSmithKline are nearly ready to seek approval for their COVID-19 vaccine. | Sanofi and GlaxoSmithKline are nearly ready to seek approval for their COVID-19 vaccine. After suffering a delay late in 2020, the partners have linked two doses of the protein vaccine to 58% protection from symptomatic COVID-19 in a variant-affected phase 3 clinical trial.", "sitename": "FierceBiotech", "date": "2022-02-23", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}